612 reports of this reaction
4.4% of all FONDAPARINUX SODIUM reports
#1 most reported adverse reaction
ANAEMIA is the #1 most commonly reported adverse reaction for FONDAPARINUX SODIUM, manufactured by Mylan Institutional LLC. There are 612 FDA adverse event reports linking FONDAPARINUX SODIUM to ANAEMIA. This represents approximately 4.4% of all 13,905 adverse event reports for this drug.
Patients taking FONDAPARINUX SODIUM who experience anaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAEMIA is moderately reported among FONDAPARINUX SODIUM users, representing a notable but not dominant share of adverse events.
In addition to anaemia, the following adverse reactions have been reported for FONDAPARINUX SODIUM:
The following drugs have also been linked to anaemia in FDA adverse event reports:
ANAEMIA has been reported as an adverse event in 612 FDA reports for FONDAPARINUX SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAEMIA accounts for approximately 4.4% of all adverse event reports for FONDAPARINUX SODIUM, making it one of the most commonly reported side effect.
If you experience anaemia while taking FONDAPARINUX SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.